869 Gemcitabine (GEM) and oxaliplatin (I-OHP) to treat immunotherapy-resistant advanced renal cell carcinoma (ARCC) patients (pts.): preliminary results of a single institution phase II study
Camillo Porta(University of Pavia), Alberto Riccardi(Istituti di Ricovero e Cura a Carattere Scientifico), Anna Natalizi(Istituti di Ricovero e Cura a Carattere Scientifico), Chiara Paglino, Ilaria Imarisio(University of Pavia), Ennio Biscaldi(Ente Ospedaliero Ospedali Galliera), Lucia Bonomi, Marco Danova(Azienda Socio Sanitaria Territoriale di Pavia), Matteo Zimatore
Cited by 0
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|275